

## Cycle view of the study programme

		Bl	Or	Th	Pr	Au	Cr
<b>Compulsory courses (B1 : 60Cr)</b>							
PHIN2004-1	<i>Active substances</i> - <i>Substances issues de recherches pharmacochimiques, part a</i> - Bernard PIROTTE - <i>Substances issues de recherches pharmacochimiques, part b</i> - Françoise DUFRASNE - <i>Substances issues des biotechnologies</i> - David VERMIJLEN - <i>Substances d'origine naturelle, part a</i> - Joëlle QUETINLECLERCQ - <i>Substances d'origine naturelle, part b</i> - Pierre DUEZ - <i>Produits radiopharmaceutiques</i> - Ghanem GHANEM	B1	Q1 10	-	-		<b>6</b>
PHIN2008-2	<i>Clinical viewpoints</i> - <i>Métabolisme des médicaments et paramètres pharmacocinétiques</i> - Roger VERBEEK - <i>Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques)</i> - Régis RADERMECKER - <i>Information et pharmacovigilance</i> - Raphaël DENOZ	B1	20	-	-		<b>6</b>
PHIN2013-2	<i>Quality assurance and pharmaceutical management</i> - <i>Principles of pharmaceutical management</i> - JeanMichel VAN DER HOFSTADT - <i>Quality assurance, part a : basic concepts and quality assurance organisation</i> - Jean SCOUVART - <i>Quality assurance, part b : Analytical technology of procedures and risk analysis</i> - Xavier MARCELIS - <i>English applied to the pharmaceutical industry</i> - Jacques POUPAERT, Nevin SERBEST - <i>Pharmaceutical marketing</i> - Vincent BIERLAIRE	B1	10	-	-		<b>7</b>
PHIN2033-1	<i>Industrial pharmaceutical technology</i> - <i>Industrial pharmaceutical microbiology</i> - Véronique FONTAINE - <i>Preformulation and selection of galenical forms</i> - Karim AMIGHI - <i>Industrial production of galenical forms</i> - Brigitte EVRARD - <i>Industrial production of biomolecules</i> - Philippe LEVEQUE, Rita VAN BEVER - <i>Industrial aspects of technological development including packaging</i> - Laurence DENIS	B1	15	-	-		<b>8</b>
PHIN2023-1	<i>Drug analysis</i> - <i>Analytical methods and pharmaceutical and biopharmaceutical control, part a</i> - JeanMichel KAUFFMAN, Pierre VAN ANTWERPEN - <i>Analytical methods and pharmaceutical and biopharmaceutical control, part b</i> - Marianne FILLET - <i>Methods in pharmaceutical and biopharmaceutical analysis, part a : Validation and qualification of equipment</i> - Philippe HUBERT, Roland MARINI DJANG'EING'A - <i>Methods in pharmaceutical and biopharmaceutical analysis, part b : Process analytical technology</i> - Philippe HUBERT, Eric ZIEMONS - <i>Statistical methods applied to the pharmaceutical industry</i> - Bernadette GOVAERTS - <i>Experimental planning and "quality by design"</i> - Bruno BOULANGER	B1	10	-	-		<b>7</b>
PHIN2029-2	<i>Regulation and the medical-social environment</i> - <i>Economic aspects of drug development</i> - Dominique MARTIN - <i>Legislation and procedures applied to pharmaceutical industry, part a : legislation</i> - Catherine DRUEZ - <i>Legislation and procedures applied to pharmaceutical industry, part b : patents and protection</i> - Patrick DI STEFANO - <i>Macroeconomic environment and pharmaco-economics</i> - Pierre DUEZ - <i>CTD File (Common Technical Document)</i> -	B1	10	-	-		<b>8</b>

	UYLDER					
	- <i>Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files</i> - Sonia BEKEN	15	-	-		
	- <i>Regulations of preclinical and clinical studies, part b : clinical studies</i> - A LENAERS	5	-	-		
	- <i>Regulations of preclinical and clinical studies, part c : pediatric studies</i> - Daniel BRASSEUR	2,5	-	-		
	- <i>Specific regulatory issues, part a : medicine and herbal dietary supplement</i> - Michel FREDERICH	5	-	-		
	- <i>Specific regulatory issues, part b : Preformulation and galenical development documentation</i> - Francis VANDERBIST	5	-	-		
PHIN2032-1	<i>Visits and seminars organised in the pharmaceutical industry</i> - Françoise DUFRASNE, Brigitte EVRARD, Rita VAN BEVER - [77,5h Vis.]	B1	-	-	[+]	<b>3</b>
MTFE2000-1	<i>Final work</i> - Françoise DUFRASNE, Brigitte EVRARD, Rita VAN BEVER	B1	-	-	-	<b>15</b>